Fresh off its historic Nasdaq listing, Elon Musk’s SpaceX is tapping public debt markets for the first time. The rockets-and-AI pioneer is capitalizing on extreme post-IPO momentum to replace short-term bridge loans with long-term bonds, funding an aggressive capital expenditure ramp. The critical financial data and infrastructure metrics behind the structural shift: ⚡ The $100...
🚀 CASH TOWER: SpaceX Enters Bond Market Armed with a Massive $100.8B War Chest
Fresh off its historic Nasdaq listing, Elon Musk’s SpaceX is tapping public debt markets for the first time. The rockets-and-AI pioneer is capitalizing on extreme post-IPO momentum to replace short-term bridge loans with long-term bonds, funding an aggressive capital expenditure ramp. The critical financial data and infrastructure metrics behind the structural shift: ⚡ The $100...
📈 WALL STREET WATCH: S&P 500 & Dow Edge Higher Amid Mideast Peace Progress
Wall Street kicked off the week with a steady advance as investors balanced positive signals from U.S.-Iran negotiations in Switzerland against impending macro and inflation data. The essential market numbers and moving catalysts: ⚡ The Midday Index Snapshot 🚀 Semiconductors Hit Record Highs 🌍 Geopolitical Relief & The Macro Shadow 💥 Biotech Blockbuster Realized In...
🛴 MICROMOBILITY FLOAT: Uber-Backed Lime Targets $1.66B Valuation in Nasdaq IPO
The global micromobility pioneer is officially hitting the public markets. Riding a powerful wave of IPO market recovery, electric bike and scooter network giant Lime has launched its U.S. roadshow, targeting a corporate valuation of up to $1.66 Billion. The critical metrics and structural data behind the impending public debut: ⚡ The $181.9 Million Capital...
💊 IMMUNOLOGY MEGA-MERGER: AbbVie Strikes $10.9B Apogee Acquisition to Defend Its $30B Franchise
Pharma giant AbbVie is executing its largest acquisition in over five years. In a definitive agreement to lock down the future of inflammatory disease treatments, AbbVie will acquire Apogee Therapeutics for a staggering $10.9 Billion in cash/debt. The vital metrics and clinical advantages driving this blockbuster biotech deal: ⚡ The $135.11 Per Share Valuation Blueprint...
🚀 AI INFRASTRUCTURE RUSH: Oaktree-Backed ITG Targets $2.7B Valuation in Nasdaq IPO
The post-SpaceX public listing boom is hitting digital infrastructure. Driven by an insatiable, AI-fueled demand for data centers and high-speed broadband connectivity, asset manager ITG has officially launched its roadshow, targeting a massive $2.67 Billion valuation in its impending U.S. market debut. The critical metrics and asset backing behind the blockbusting float: ⚡ The $429M...
